




TTY Biopharm 4105

Operational Results Report



2025.11.26

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook

01 Q1~Q3/2025 Operational Highlights




TTY Strategy Enhances Operational Performance

Revenue Overview

Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook





Unit : Million

Market Development Highlights

Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook



Strong growth in overseas sales

Lipo-AB's sales in the US is steadily increasing, and its market share in the US continues to grow. The cumulative US export share for 2025 up to Q3 is approximately 10%.*

*TTY Individual Net Sakes Ratio



Flu vaccine sales driven both public & private funded

Increased proportion of public funded; significant growth in the self-funded market; adjuvant vaccines target the elderly market.



Significant Achievements in Self-Developed and Domestically Produced New Drugs

The new antibiotic Bobimixyn has been launched, meeting the needs of later-line clinical trials.

Three Arrows of Operation with Outstanding Results

Q1~Q3/2025
Operational
Highlights

Export
Difficulty
Generic Drugs

Launch the Drug Licenses Submission Globally

- US sales performance hit the leap in growth.
- Passed US factory inspection.
- Saudi Arabia, Australia, Vietnam, the Philippines, Jordan, and Hong Kong have applied licenses and registration procedures for submitted documents.

Q1~Q3/2025
Financial
Performance

License-in
International New
Drugs

Access to Global Therapies

- Minjuvi, a new ingredient & new drug for Lymphoma launched with new treatment options.
- Asia's first adjuvanted flu vaccine to be funded by the government in 2026.
- In line with the EU, adjuvanted flu vaccines will be available to adults aged 50 and over in 2026.
- Expanding the vaccine product line by introducing the TTY_B varicella vaccine.

Cross-Border Corporate Collaboration

- Product Strategy Alliance on Avastin/Rozlytrek.
- Xpovio offers a complete product line for hematoma treatments.

2026 Outlook

Self-developed
New Drugs/
Generic Drugs

Strengthened Supply Resilience

- First domestically developed targeted lung cancer drug, TTY_A, received license in Q4/2025.
- Fustron's milestones: the launch of a new breast cancer treatment and a record-breaking achievement.
- Bobimixyn, the first new antibiotic drug, with impressive marketing performance.
- Algitab Chewable Tablets received medical association treatment consensus.

Emerging Combination Therapy Trends

- Self-made product, Pexeda combined with IO therapy (Keytruda).
- Self-made Leavdo+Minjuvi monoclonal antibody.

OkaBIK Varicella Vaccine

Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook



Suitable for children 12 months and older

In addition to distributing CSL Seqirus cell influenza vaccine and adjuvanted influenza vaccine, TTY continues to expand distribution to include BIKEN's varicella vaccine.

Immunization of children over 12 months of age, adolescents and adults to prevent chickenpox infection.



Taiwan Selection



Oka Strain

The varicella vaccine is a routine vaccine, with the first dose subsidized by the government. Bidding will commence in the 4th quarter of 2025, and supply is expected to begin in the 4th quarter of 2026.







First approved in Japan in 1984, it has been used for 40 years. Currently, most varicella vaccines used worldwide are still based on the Oka strain.



publicly funded market for chickenpox vaccines

Product Pipeline: Self-develop, License-in, Cooperation

- Alliance with international partners to strengthen the advantage of the product portfolio
- Joint-develop specialty of generic drugs with international partners and expand overseas markets

Oncology	2025	2026	2027
TTY_A (Lung Cancer NSCLC)			
Intensive Care	2025	2026	2027
TTY_2D (Skin tissue infections and bacteremia caused by Gram-positive bacteria)			
TTY_3T			
TTY_3D			
Specialty	2025	2026	2027
Lipo-AB (Liposomes) : EU			
OT2015 (Microspheres) : US			

Note: those without marked are in Taiwan

02 Q1~Q3/2025 Financial Performance



Q1~Q3/2025 Financial Performance

Operational Results Report

Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook

Income Statement (Unit: NT Thousand, except EPS)	2025 Q1~Q3	2024 Q1~Q3	YoY %
Net Sales	4,790,870	4,181,720	15%
Operating Cost	(2,007,149)	(1,649,981)	22%
Gross Profit	2,785,701	2,526,864	10%
Gross Margin (%)	58%	61%	
Operating Expenses	(1,439,224)	(1,483,468)	-3%
Operating Profit	1,346,477	1,043,396	29%
Operating Margin (%)	28%	26%	
Non-operating Income	332,380	173,739	91%
Profit before Tax	1,678,857	1,217,135	38%
Net Income (Consolidated)	1,329,752	975,799	36%
Net Margin (%)	28%	23%	
Net Profit Attributable to Owners of the Parent Company	1,255,910	915,116	
EPS (Unit : NTD)	5.05	3.68	

Financial Performance

- YoY consolidated revenue was 47.9 billion, +15% due to the high growth of overseas markets and reinvestment; a significant contribution of influenza vaccines to Intensive Care BU, and Oncology BU increased steady as well.
- YoY consolidated operating gross profit at 58%, and it's a bit less than the same period last year.
- Non-operating income increased by 91% due to the recognition of settlement in overseas markets.
- Net income after tax was 1.33 billion, and the net profit attributable to owners of the parent company was 1.26 billion, and EPS was NT\$5.05, representing a year-over-year increase of NT\$1.37.

Q1~Q3/2025 Steady Revenue Growth


Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook


Q1~Q3/2025 Revenue Breakdown

Product Category %



Q1~Q3/2025 Revenue Growth

Revenue (NT Mn)



Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook

03 2026 Outlook



2026年度展望



Q1~Q3/2025
Operational
Highlights

Q1~Q3/2025
Financial
Performance

2026 Outlook

1

Expanding collaboration & overseas market

- **Lipo-AB:**
 - Expected to obtain licenses from Saudi Arabia, Australia, and Jordan
 - Deploy the market in Southeast Asia and South America
- **Leavdo launched in Singapore**
- **Continue to cultivate Southeast Asian markets such as Vietnam and South Korea**

2

Licensing In & Self-developed

- **Deepen cooperation with international factories and stabilize licensing-in cases**
- **Establish domestic technology transfer model**
- **Launch licensing-in products annually, expanding operational performance**
 - New drug TTY_A launched
 - Achieved Xpovio distribution
- **Self-developed new products**
 - Launched antibiotics DP and TZ are on the market

3

Cost Reduction & Process Improvement

- **Supply chain management**
- **Improve the R&D of generic drugs and domestically produced new drugs**
- **Expanding production capacity in response to future market demand**
- **Introduction of domestic and foreign professionals**
- **Implementing ERP (SAP) to optimized and improved operational efficiency continuously.**
- **Optimize management reports to support operations management and strategic planning.**